CRI's new website that seeks to engage, educate, and empower patients and their loved ones to learn more about cancer immunotherapy as a treatment option across numerous tumor types.
Cancer patients, donors, scientists, and other supporters all stand behind the Cancer Research Institute. Read their stories and learn about what motivates each of us to keep fighting against cancer.
By running in a marathon or hosting a bake sale, you can make a real difference for our scientists in the fight against cancer and allow them to bring newer immunotherapies to more patients.
We gratefully accept donations made in memory or in honor of a loved one. Your gift will be acknowledged to whomever you specify.
Hosted by CRI, EATI, CIMT, and AACR, register today for "Translating Science into Survival," on September 16-19, 2015, in New York City.
Curious about the latest developments in cancer immunotherapy research? Listen in as leading scientists discuss immune-based treatments across numerous cancer types in our free "Breakthroughs in Cancer Immunotherapy" webinar series.
When the Cancer Research Institute was founded in 1953, we knew then that immune-based treatments would transform cancer medicine. In more than six decades since, we've made numerous groundbreaking discoveries that have given more patients new hope today.
Welcome to the Cancer Research Institute blog. Here we share the latest updates on the field of cancer immunotherapy from CRI, including scientific breakthroughs, news stories, and program announcements. We invite your comments and encourage you to share these stories with your friends.
You can receive notifications of new posts by subscribing to our blog. Just click the RSS icon in the upper right corner.
August 25, 2015
The drug, known as a beta-blocker, is taken by millions of people every year, but not for cancer.
antibody, checkpoint blockade, immunotherapy, melanoma, patients
Jedd Wolchok, lloyd old, scientific leadership
community fundraising, marathon, Team CRI
fellows, grants, immunotherapy, research awards
awareness, Cancer Immunotherapy Month
AACR, Cancer Immunity, Cancer Immunology Research, collaboration, publication
emma whitehead, HIV, immunotherapy, leukemia, patients
checkpoint-inhibitor, CTLA-4, immunotherapy, ipilimumab, James Allison
ASCO, cancer, drug, experimental, lung cancer, NBC Nightly News, PD-1, T cell